Prosecution Insights
Last updated: November 20, 2026

Kristen Wang Romero, USPTO Patent Examiner

Listed by the USPTO as ROMERO, KRISTEN WANG

Tech Center 1600 • Art Units: 1624 1625 1626 1629

This examiner grants 70% of resolved cases

Analysis

ROMERO, KRISTEN WANG is a Tech Center 1600 examiner assigned to art unit 1624, with 54 resolved cases. The allowance rate is 70.4%, and the median time to allowance is 1161 days. The case volume offers useful initial context, although it is smaller than a mature examiner docket, and the median timeline should be considered in prosecution planning.

The interview lift is 30.8%, suggesting that interviews may assist in moving cases toward allowance. Practitioners may wish to prepare focused interview points while preserving a complete written response. The listed companies are Shanghai Apeiron Therapeutics Company Limited, THE GENERAL HOSPITAL Corporation, and Vanderbilt University. The listed firms are BALLARD SPAHR LLP, ARENTFOX SCHIFF LLP, and BakerHostetler.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

70.4%
Allow Rate
+10.4% vs TC avg
96
Total Applications
+30.8%
Interview Lift
1161
Avg Prosecution Days
Based on 54 resolved cases, 2023–2026

Rejection Statute Breakdown

4.1%
§101 Eligibility
19.4%
§102 Novelty
20.4%
§103 Obviousness
39.5%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18263384 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES Non-Final OA The General Hospital Corporation
18399675 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER Non-Final OA INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
18605320 Compositions of Azadirachta Indica and Methods of Treating Cancer Non-Final OA Board of Regents, The University of Texas System
18728949 ISOCITRATE DEHYDROGENASE 1 INHIBITORS AND METHODS OF USE THEREOF Non-Final OA CASE WESTERN RESERVE UNIVERSITY
18615330 DEVELOPMENT AND OPTIMIZATION OF THIOCHROMENOTHIAZOLE-BASED MSUT2 INHIBITORS AS CANDIDATES FOR THE TREATMENT OF TAUOPATHY Non-Final OA The United States Government As Represented By the Department of Veterans Affairs
18719260 METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF Non-Final OA Alexion Pharmaceuticals, Inc.
18688087 COMPOUNDS AND METHODS FOR MODULATING SPLICING Non-Final OA REMIX THERAPEUTICS INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Kristen Wang Romero's allowance rate?

70.4% of resolved applications examined by Kristen Wang Romero were allowed (54 resolved cases), compared with 54.4% across Art Unit 1624 over the last five years.

Does an interview help with examiner Kristen Wang Romero?

This examiner's interview lift is +30.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Kristen Wang Romero take to allow a patent?

Applications allowed by Kristen Wang Romero took 1,161 days on average from filing to allowance.

Which art unit does examiner Kristen Wang Romero work in?

Kristen Wang Romero examines applications in Art Unit 1624 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month